New · The Impact Gap Report 2026: why physicians stopped reading pharma’s science. Get it free →
PubVisualPubVisual Book a Demo
Resources Blog About Contact Book a 30-Minute Demo →
Pharma Animation

Pharma animation physicians actually finish.

Your science is world class. The formats it travels in are not. We turn your approved source into experiences physicians steer: they open what they came for, choose their depth, and take an approved next step. Understood beats watched.

The science teams behind the world’s leading therapies Bayer Takeda Bristol Myers Squibb Daiichi Sankyo UCB Regeneron
Proof you can drag

Give your figure a user interface.

On the left, the data the way a PDF delivers it. On the right, the same approved science as physicians meet it in a PubVisual. Same data. Drag the handle.

The same data as an explorable PubVisual
The PDF The PubVisual

You just did more with that figure than a PDF allows. One drag, and the same approved data went from a page someone skims to a screen someone drives. That difference is the whole company.

The category, honestly

Pharma animation is not the outcome. Understanding is.

An animation that only plays is still a monologue.

A physician gives your science a few minutes, and a film that runs the same for everyone spends most of them on parts that reader did not need. So we build animation physicians can steer: open the part they came for, choose the depth, take an approved next step inside the science. Nothing new is created. Every frame maps back to the source you approved, which is why it is built for MLR from the first frame.

One animation, two desks

One brand animation. Two desks. Two ways through.

The same approved animation goes to the brand team and to medical affairs. Tap a desk and watch what each of them opens first. Neither wades through the other’s part, and it is all one MLR review.

Your approved brand animationOne source. One review. One link.
The story leadTheir route through the animation
1
2
3
Same animation, two reads, one review. Both desks work from one approved source, so the story cut never drifts from the claims map and one MLR pass covers the whole thing. That is what keeps the campaign and the science in the same room.
Start from the job

What are you trying to explain?

The science decides what it needs to become. Hover through the jobs, then open the one that sounds like the problem on your desk.

Now playing
Mechanism of action, explorable
3D where the shape is the story
Trial readout, explorable
Patient education at the right level
Congress poster that keeps answering
Value story payers can navigate
The mechanism, retainedOpen the page →
FREEThe Impact Gap Report · 2026

The document that settles the "is anyone reading this?" argument.

60+ studies on why physicians stopped reading pharma’s science, and the evidence for what works instead. Sourced, quotable, built for forwarding.

Get it now · free →
PubVisualby RedNovius
THE IMPACT GAP REPORT · 2026
Pharma keeps publishing. Physicians stopped reading.
What 60+ studies say about the gap between published and understood.
Every job has its page

Start from the job, not the format.

Each page below is one thing your science has to do. You bring the paper and the therapeutic-area context. We do the heavy lifting.

One source. One review. Everywhere it goes.

Build the approved core once, and it carries across every experience and every market. Every frame maps back to your source, so all of it stays built for MLR.

30+Build the core once. It carries every language, whatever it becomes.
0new claims. Everything maps to the approved source.
1MLR review covers every version, not per asset.
“One team, one source, and everything we needed came out of it.”
Head of Scientific Communications · Oncology
See it on your own science

Bring us your science.

Send the paper, the poster, or the value story. We will show you what it would become and how physicians would explore it. On the house. No promises.

NEWFREE REPORT · 2026

Pharma keeps publishing. Physicians stopped reading.

The document that settles the argument: 57 pages of evidence on why your science isn’t landing, and what to do about it.

  • Every number for your next strategy meeting, on its own page, source linked
  • The final chapter: what the evidence says actually works
  • Built to forward · send it to whoever owns the publication plan
Get it now · free →
Questions

Frequently asked questions

A video is often step one, and sometimes it is all a piece of science needs. But the reason teams come to us is what sits on top: the physician can explore the content, it adapts to what each physician explores, and interest becomes an approved next step inside the story. Animation is the ingredient. Understanding is the product.

That depends on the job it has to do, and we will be straight with you about it, including where 3D earns its place and where a simpler build lands faster. Send us the source and we will show you the options on your own material.

Yes, that is the point. Build the approved core once and it carries into the mechanism story, the trial readout, the patient version, and the congress follow-up, without starting the science over each time.

Our in-house scientific team builds everything from the source you approve, and you review at every step. You bring the paper and the therapeutic-area context. We do the heavy lifting.

We will not tie it to a fixed date. You approve the core the normal way, at script, storyboard, and final animation. From there, that same approved core carries every version, so new cuts and languages do not restart the scientific review. The overall pace tracks your own review, which we plan around with you from day one.

Yes. Everything we build, without exception, maps each frame to an approved claim, so it is structured for MLR from the first frame and fits your existing Veeva workflow.